A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.

MLA

Harrison, Stephen A., et al. “A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of Efruxifermin for Patients with Compensated NASH Cirrhosis.” JHEP Reports : Innovation in Hepatology, vol. 5, no. 1, Aug. 2022, p. 100563. EBSCOhost, https://doi.org/10.1016/j.jhepr.2022.100563.

APA

Harrison, S. A., Ruane, P. J., Freilich, B., Neff, G., Patil, R., Behling, C., Hu, C., Shringarpure, R., de Temple, B., Fong, E., Tillman, E. J., Rolph, T., Cheng, A., & Yale, K. (2022). A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Reports : Innovation in Hepatology, 5(1), 100563. https://doi.org/10.1016/j.jhepr.2022.100563

Chicago

Harrison, Stephen A, Peter J Ruane, Bradley Freilich, Guy Neff, Rashmee Patil, Cynthia Behling, Chen Hu, et al. 2022. “A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of Efruxifermin for Patients with Compensated NASH Cirrhosis.” JHEP Reports : Innovation in Hepatology 5 (1): 100563. doi:10.1016/j.jhepr.2022.100563.